Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:31:38 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:CABA from 2023-04-30 to 2024-04-29 - 27 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-21 07:00U:CABANews ReleaseCabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-03-20 07:00U:CABANews ReleaseCabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
2024-02-27 08:00U:CABANews ReleaseCabaletta Bio to Participate in Upcoming Investor Conferences in March
2024-02-01 16:30U:CABANews ReleaseCabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
2024-01-31 08:00U:CABANews ReleaseCabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2024-01-08 07:00U:CABANews ReleaseCabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
2024-01-02 08:00U:CABANews ReleaseCabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-28 16:30U:CABANews ReleaseCabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
2023-11-09 07:00U:CABANews ReleaseCabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-06 08:15U:CABANews ReleaseCellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta ¢ € ™s CD19-CAR T Cell Therapy on Cellares ¢ € ™ Cell Shuttle Platform
2023-11-06 07:00U:CABANews ReleaseCabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
2023-10-30 08:00U:CABANews ReleaseCabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
2023-10-02 07:00U:CABANews ReleaseCabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
2023-09-19 08:00U:CABANews ReleaseCabaletta Bio to Participate in Upcoming Investor Conferences in September
2023-08-30 08:00U:CABANews ReleaseCabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
2023-08-22 08:00U:CABANews ReleaseCabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
2023-08-10 07:00U:CABANews ReleaseCabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-07-24 08:00U:CABANews ReleaseCabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
2023-06-20 08:00U:CABANews ReleaseJasper Therapeutics Appoints Scott Brun, M.D., ‚  to its Board of Directors
2023-05-31 08:00U:CABANews ReleaseCabaletta Bio to Present at the Jefferies Healthcare Conference
2023-05-22 16:30U:CABANews ReleaseCabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
2023-05-17 22:16U:CABANews ReleaseCabaletta Bio Announces Pricing of Public Offering of Common Stock
2023-05-17 16:01U:CABANews ReleaseCabaletta Bio Announces Proposed Public Offering of Common Stock
2023-05-16 07:00U:CABANews ReleaseCabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
2023-05-11 07:00U:CABANews ReleaseCabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update
2023-05-02 16:35U:CABANews ReleaseCabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting
2023-05-01 07:00U:CABANews ReleaseCabaletta Bio Receives FDA Fast Track Designation for CABA-201